Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform

The US FDA is planning a guidance on Alzheimer's drug development, part of a broader reform of the Office of New Drugs (OND).

The guidance-writing initiative is intended to articulate modern evidentiary and clinical trial design expectations in specific disease areas where the...